Eduardo Maximiano Silva *

Autor invitado por SIIC

NOVOS BENEFÍCIOS DAS ESTATINAS EM IDOSOS

As estatinas são drogas que inibem uma enzima participante do processo de biossíntese do colesterol endocelular, resultando, em última instância, na diminuição dos níveis de colesterol circulante no plasma e indicadas, classicamente, para o tratamento da dislipidemia.

*Eduardo Maximiano Silva
describe para SIIC los aspectos relevantes de su trabajo
NOVOS BENEFÍCIOS DAS ESTATINAS EM IDOSOS
Institución principal de la investigación
*Universidade Catolica de Brasilia, Brasilia, Brasil
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Amarenco P, Lavalle P, Toulboul PJ. Statins and stroke prevention. Cerebrovasc Dis, 17, suppl 1:81-88, 2004.2. Aronow WS. Pharmacologic therapy of lipid disorders in the elderly. Am J Geriatr Cardiol, 11(4): 247-256, 2002.3. Benner JS, Glynn RJ, Mogun H. Long-term persistence in use of statin therapy in elderly patients. JAMA, 288:455-461, 2002.4. Buckert E. et al. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriatr 12(3):225-231, 2003.5. Bucley B. Lipids and stroke. Br J Diabetes Vasc Dis 3(3):170-176, 2003.6. Crsiby M. Cholesterol, statins and dementia: how could lipid-lowering strategies prevent neurodegeneration Geriatrics & Aging 6(8):49-55, september 2003.7. Del Carlo CH, Barreto ACP. Inibidores da HMG CôA redutase e insuficiência cardíaca. Jornal da Insuficência Cardíaca 5(1):5-8, 2004.8. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased mineral density in postmenopausal women. The Lancet 355:2218-2219, 2000.9. Ford I, Blaw GJ, Murphy MB. A prospective study of pravastatin in the elderly at risk (PROSPER): screening experience and baseline characteristics. Curr Controlled Trials Cardiovasc Med 3(8):1-8, 2002.10. Jick H, Zornberg GL et al. Statins and the risk of dementia. The Lancet 356:1627-1631, 2000.11. Mano R. Os redutores da HMGCoA redutase- as vastatinas. Disponível em http://www.manuaisdecardiologia.med.br/Dislipidemia/Lipid5.htm Acesso em 20 mar. 2004.12. Miura DS. Controversies in the treatment of hypercholesterolemia in the elderly: who should be treated and how Am J Geriatr Cardiol 10(3):152-158, 2001.13. Moriguchi EH, Michelon E, Vieira JLC. Dislipidemia em idosos. In: Freitas EV et al. Tratado de Geriatria e Gerontologia. Rio de Janeiro: Guanabara Koogan, 2002. p. 239-248.14. Rockwood K et al. Use of lipid-lowering agents, indication bias and the risk of dementia in community-dwelling elderly people. Arch Neurol 59(2):223-227, 2002.15. Stone NJ. Are statins indicated for the primary prevention of coronary heart disease in octogenarians Protagonist viewpoint. Am J Geriatr Cardiol 12(6):351-356, 2003.16. Tsunekawa T. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly patients within 3 days. Circulation 104:376-379, 2001.17. Watts N. Bisphosphonates, statins, osteoporisis and atherosclerosis. South Med J 95(6):78-582, 2002.18. Mundy G, Garret R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-49,1999.19. Bauer D, Mundy G, Jamal S et al. Statin use, bone mass and fracture: an anlysis of two prospective studies. J. Bone Miner Res 14 (suppl):S179, 1999.20. Tan ZS, Seshadri S, Beisser A et al. Plasma total cholesterol level as a risk factor for Alzheimer’s disease. The Framingham Study. Arch Intern Med 163:1053-7, 2003.21. Sacco RL, Benson RT, Kargman DE et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 285:2729-35, 2001.22. Botts ML, Elwood PC, Niitin Y et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe.J Epidemiol Community Health 56(suppl 1):I 19-24, 2002.